

Chicago Specials

Fall Group Meeting

OCTOBER 8 - 10, 2026



Early Therapeutics & Rare Cancers
Committee

Early Therapeutics & Rare Cancers Committee

Leadership

Chair: Razelle Kurzrock, MD
 Vice-Chair: Young Kwang Chae, MD, MPH
 Executive Officer: Neeraj Agarwal, MD
 Statisticians: Megan Othus, PhD
 Alejandro Hernandez, MS
 Anna B. Moseley, MS
 Sara Threlkel, BS

Liaisons

Breast Committee Liaison: Stephanie L. Graff, MD
 Cancer Control Liaison: Jason M. Prosek, MD
 Lara E. Davis, MD (Survivorship)
 Genitourinary Committee Liaison: Parminder Singh, MD
 Imaging: TBD
 Lung Committee Liaison: Shirish M. Gadgil, MD
 Lymphoma Committee Liaison: Nasheed Mohammad Hossain, MD
 Melanoma Committee Liaison: TBD
 Myeloma Committee Liaison: Frits van Rhee, MD, PhD

Designates

Data Coordinator: Christine Magnier
 Veterans Affairs: Jimmy Ruiz, MD
 Oncology Research Professionals: Adam Platt, BS
 Pharmaceutical Science: Craig Elg, PharmD
 Sun "Coco" Yang, PharmD, PhD
 Patient Advocate: Bill Minh Thach, MBA
 Protocol Project Manager: Catrina De Los Santos-Mireles
 Clinical Trials Program Manager: Laura Gildner, MS

Time/Location

Thursday, October 8, 2026 11:00 a.m. - 1:30 p.m.

Room: Registry C (Ballroom Level)

Agenda

11:00 - 11:10 am	Welcome and Introduction - Razelle Kurzrock, MD
11:10 - 11:35 am	SN2426, "A Randomized Phase II Study of Amivantamab Versus Cetuximab in Immunocompromised Participants with Recurrent Inoperable or Metastatic Cutaneous Squamous Cell Carcinoma 21CTP.HN01, "CAPT-HN-A Phase II Study of Combined Amivantamab, Carboplatin, and Paclitaxel in Unresectable Locally Recurrent or Metastatic Head and Neck Cancer - Paul Swiecki, MD

11:35 - 12:00 pm	MRD Concept - Young Kwang Chae, MD, MPH, MBA
12:00 - 12:25 pm	Updates from Sarcoma Working Group & S2505, "Phase III Randomized Study Testing Non-Inferiority of Short-Course Ultra-Hypofractionated Radiation (UHRT-5) Versus Standard FRACTIONATION (RT-25) for Stage II-IIIb, Extremity, Resectable Soft Tissue Sarcoma." - Lara Davis, MD & Jeremy Harris, MD, MPhil
12:25 - 12:50 pm	Overview of Additional Analyses of DART - Megan Othus, PhD
12:50 - 1:15 pm	MD Anderson Cancer Center, NCI CIMAC (Cancer Immune Monitoring and Analysis Centers) Updates on S1609: Treatment with Ipilimumab and Nivolumab for Rare Cancers (DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors) - Cara Haymaker, PhD
1:15 - 1:30 pm	Wrap Up - Razelle Kurzrock, MD

Active Studies

S2505, "Phase III Randomized Study Testing Non-Inferiority of Short-Course Ultra-Hypofractionated Radiation (UHRT-5) Versus Standard FRACTIONATION (RT-25) for stage II-IIIb, extremity, resectable Soft Tissue Sarcoma". Drs. Harris, Davis. Activated: 7/6/2026.

SN2426, "A Randomized Phase II Study of Amivantamab (JNJ-61186372) and hyaluronidase (rHuPH20) versus Cetuximab in Immunocompromised Participants with Recurrent Inoperable or Metastatic Cutaneous Squamous Cell Carcinoma." Dr. Swiecicki, Geiger (NRG Study Chair) Activated: 1/28/2026.

S2012, "Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)." Drs. Zhen, Chiorean, Burgess, Swisher. Activated: 12/2/21.

CTSU/A071401, "Phase II Trial of SMO/AKT/NF2/CDK Inhibitors in Progressive Meningiomas with SMO/AKT/NF2/CDK Pathway Mutations." Dr. Brastianos. SWOG Champion: Dr. Piccioni. Activated: 8/28/2015. New patient registration (Step 1) to the NF2, CDKN2A, CDK4, CDK6, CCND1, CCND2, CCND3, and CCNE1 Cohort (Abemaciclib Cohort) is closed to accrual as of 10/03/2022.

CTSU/A092001, "Phase 2 Randomized Trial of Neoadjuvant or Palliative Chemotherapy with or Without Immunotherapy for Peritoneal Mesothelioma". SWOG Champion: Dr. P.S.K. Raghav. Activated: 10/15/21.

Early Therapeutics & Rare Cancers Committee

CTSU/AGCT1531, "A Phase III Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors" SWOG Champion: Dr. D'Souza Activated: 5/8/17. Stratum 2 is temporarily closed to accrual 12/17/2024.

CTSU/AOST2031, "A Phase 3 Randomized Controlled Trial Comparing Open vs Thorascopic Management of Pulmonary Metastases in Patients with Osteosarcoma" SWOG Champion: Dr. Hofstetter. Activated: 2/15/22

CTSU/AOST2032, "A Feasibility and Randomized Phase 2/3 Study of the VEGFR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma" SWOG Champion: Dr. J. A. Livingston. Activated: 2/17/23 Temporarily Closed to Accrual as of 09/06/2023

CTSU/ HN.11 (CCTG-HN11), "SPECT-CT Guided Elective Contralateral Neck Treatment (SELECT) for Patients with Lateralized Oropharyngeal Cancer: A Phase III Randomized Controlled Trial SWOG" Champion: Dr. Paul Swiecicki. Activated: 9/29/22

Studies in Development

S2702, "A Randomized Phase II/III Trial of Zanzalintinib Plus Temozolomide and Gemcitabine Plus ATX-101 Versus Gemcitabine and Docetaxel in Patients with Unresectable or Metastatic Leiomyosarcoma". Dr. Mark Agulnik

"A Randomized Phase II Trial to Evaluate Frontline Combination Immunotherapy of Cemiplimab, Fianlimab, Carboplatin, and Paclitaxel versus Investigator Choice Anti-PD-1/ PDL1 based Chemo-ICI for Metastatic Large Cell Neuroendocrine Carcinoma of the Lung: FIRST-LUNG". Dr. Naqash

Closed Studies

CTSU/A071702, "A Phase II Study of Checkpoint Blockade Immunotherapy in Patients with Somatic Hyper-mutated Recurrent Glioblastoma." SWOG Champion: Dr. M. Ahluwalia. Activated: 10/30/20. Pre-Registration is temporarily Closed to accrual 12/12/23. Closed: 06/02/2025.

CTSU/EA2183, "A Phase III Study of Consolidative Radiotherapy in Patients with Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma." Dr. Uboho. SWOG Champion: Dr. Saeed. Activated: 2/6/20. Closed: 05/23/2025

CTSU/A071601, "Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas." Dr. Brastianos. SWOG Champion: Dr. Ahluwalia.

Activated: 8/4/17. Temporarily Closed (Cohort A): 9/8/20. Closed: 05/10/2024

S1609, "DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors." Drs. Patel, Chae, and Kurzrock. Activated: 1/13/17. Closed: 3/15/23.

CTSU/NRG-GY006, "A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer." Dr. Leath. SWOG Champion: Dr. Robinson. Activated: 1/15/16. Closed: 9/22/22

CTSU/NRG-GY020, "A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer." Dr. Backes. SWOG Champion: Dr. Robinson. Activated: 2/7/20. Closed: 8/29/22.

NCICOVID, "NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study." Dr. Karim. Activated: 5/21/20. Closed: 2/1/2022.

CTSU/NRG-GY009, "A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer." Dr. O'Cearbhaill. SWOG Champion: Dr. Robinson. Activated: 5/12/17. Closed 10/14/2021

CTSU/NRG-HN007, "An Open-Label, Phase III Study of Platinum-Gemcitabine with or without Nivolumab in the First-Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma." Dr. Brigitte B. Y. Activated: 9/8/20; Closed: 10/28/21

CTSU/EAY131, "Molecular Analysis for Therapy Choice (MATCH)." Activated: 8/12/2015. Closed: 12/23/2022

CTSU/NRG-BN007, "A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab versus OV1821BN1 Temozolomide in Patients with Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma." Dr. Lassman. SWOG Champion: Dr. Ahluwalia. Activated: 8/6/20. Closed: 3/29/23.

Early Therapeutics & Rare Cancers Committee

CTSU/EA3163, "Phase II Randomized Trial of Neoadjuvant Chemotherapy Followed by Surgery and Post-Operative Radiation versus Surgery and Post-Operative Radiation for Organ Preservation of T3 and T4a (and Selected T4b) Nasal and Paranasal Sinus Squamous Cell Carcinoma (NPNSCC)." Dr. Saba. SWOG Champion: Dr. Swiecicki. Activated: 3/28/18. Closed: 11/7/23

Proposed Studies

NRG-BN1803, "NRG-COG Phase II Trial of Radiation Plus Concurrent and Adjuvant ONC201 for Newly Diagnosed, H3 K27M-Mutant Gliomas." SWOG Champion: Dr. Ahluwalia.

NRG-OV1821, "A Randomized Phase II Trial of Olaparib Versus Olaparib + Tremelimumab in Platinum-Sensitive Recurrent Ovarian Cancer." Dr. Robinson.

NRG-BN1855, "A Randomized Phase II/III Open Label Study of Ipilimumab and Nivolumab Vs Te-mozolomide in Patients with Newly Unmethylated MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Glioblastoma." Dr. M. Ahluwalia.

NRG-HN1854, "An Open-label, Phase III Study of Platinum-Gemcitabine with or Without Nivolumab in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma." Dr. P. Swiecicki.

NRG-UC1805, "Randomized Phase III Trial of Radiation +/- Pembrolizumab for High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer." Dr. W. Robinson.

ComboMATCH Studies in Development

EAY191-S9, "Phase II Study of Inavolisib in Combination with Ribociclib in PIK3CA Aberrated Head & Neck or NSMP Endometrioid Endometrial Cancers." Drs. B. Nelson and J. Rodon.

ComboMATCH Closed Studies

EAY191-S3, "Phase 2 Study of Paclitaxel + Ipatasertib in Taxane-Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors." Drs. R. Basho and H. Mahdi. Activated: 3/6/23. Closed: 8/3/26.

CTP Active Studies

21CTP.HN01, CAPT-HN: "A Phase II Study of Combined Amivantamab, Carboplatin and Paclitaxel in Unresectable Locally Recurrent or Metastatic Head and Neck Cancer." Drs. Swiecicki, Rodriguez, and Brenner. Activation: 09/15/2025

Publications

The publication papers listed below from 2026 have not appeared as published in previous Group Meeting publications listings. Accepted and submitted manuscripts are also listed, with the journal names withheld to honor journal embargo policies. Conference abstracts are not included.

Published/Accepted Manuscripts

S1609 DART/SWOG/NCI phase II anti-CTLA-4/PD-1 trial: clear cell carcinomas of ovary, endometrium, cervix. Chae YK, Othus M, Patel S, Backes F, O'Malley D, Cristea M, Naing A, Kurnit K, Eskander R, Goodrich S, Robinson W, Kim H, Chung L, McLeod C, Chen H, Sharon E, Streicher H, Ryan C, Blanke CD, Kurzrock R. *Journal for the ImmunoTherapy of Cancer*. 2026. <https://pubmed.ncbi.nlm.nih.gov/41672597/>

S1609 Evaluation of mixed response in tumor size and survival in patients with rare cancers treated with dual checkpoint inhibitor therapy (DART SWOG S1609). Chae YK, Othus M, Lyu J, Lee S, Paik S, Dietrich E, Jung CM, Chung LI, Patel S, Kurzrock R. *Journal for ImmunoTherapy of Cancer*. 2026. <https://pubmed.ncbi.nlm.nih.gov/41819545/>

S1609 DART (NCI/SWOG S1609): Comprehensive Final Results from Dual Checkpoint Inhibition with CTLA-4 and PD-1 Blockade in Rare Cancers. Patel SP, Othus M, Chae YK, Azenkot TA, Alviz C, Threlkel S, Haymaker C, Streicher HZ, Magner CM, Chen HX, Sharon E, Ryan CW, Blanke CD, Kurzrock R. *Annals of Oncology*. 2026. <https://pubmed.ncbi.nlm.nih.gov/41997295/>

S1609 A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: vaginal cancer sub cohort results. Chae YK, Czeskleba J, Patel SP, Mentor A, Robinson W, Jones NL, Rampurwala M, Naing A, Beck JM, Moloney-Lineen C, Chung LI, McLeod CM, Chen HX, Sharon E, Threlkel S, Othus M, Ryan CW, Blanke CD, Kurzrock R. *Journal of Gynecologic Oncology*. 2026. <https://pubmed.ncbi.nlm.nih.gov/41995270/>

S1609 A phase II basket trial of DART SWOG S1609: the salivary gland tumor cohort. Chae YK, Sun R, Patel SP, Giles F, Ohr JP, Worden FP, Suga JM, Naing A, Cohen EE, Wallace J, Kang HS, Fenton S, Chung LY, McLeod CM, Chen HX, Sharon E, Streicher H, Ryan CW, Othus M, Blanke CD, Kurzrock R. *Therapeutic Advances in Medical Oncology*. 2026. <https://pubmed.ncbi.nlm.nih.gov/42499790/>

Early Therapeutics & Rare Cancers Committee

Submitted Manuscripts

S1609 Outcomes of Adolescent and Young Adult (AYA) Patients versus Patients Ages 40 and Older with Rare Solid Tumors Treated with Nivolumab plus Ipilimumab (NCI/SWOG S1609: DART trial). Othus M, Davies M, Alviz C, Chae YK, Patel SP, Kurzrock R. Submitted 2026.

S1609 Outcomes of Patients with Rare Cancers Treated with Combination Immune Checkpoint Inhibitors With and Without Lung and/or Liver Metastases (NCI/SWOG S1609). Wang Y, Othus M, Chae YK, Davies M, Dietrich E, Patel SP, Kurzrock R. Submitted 2026.

Early Therapeutics & Rare Cancers Committee

Accrual from trials that are open as of 6/30/2026 or have closed in the prior 18 months, by Institution and Study

	S2012	SN2426	EAY191-S3	21CTP HN01	A071401	AGCT1531	AGCT1532
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	1	-	-	-	-	-	-
Cancer Research Consortium of West Michigan NCORP	1	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	3	-	-	-	-	-	-
Carolinas Medical Center/Levine Cancer Institute	7	-	-	-	-	-	-
Cedars-Sinai Medical Center	-	-	2	-	-	-	-
CommonSpirit Health Research Institute	1	-	-	-	1	-	-
Duke University - Duke Cancer Institute LAPS	-	-	1	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	18	-	-	-	-	-	-
Froedtert and the Medical College of Wisconsin LAPS	3	1	-	-	-	-	-
Gulf South Clinical Trials Network (Gulf South NCORP)	4	-	-	-	-	-	-
Heartland Cancer Research NCORP	2	-	-	-	-	-	-
Henry Ford Hospital	2	-	-	-	1	-	-
Kaiser Permanente NCI Community Oncology Research Program	6	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	5	-	1	-	-	-	-
Moffitt Cancer Center	10	-	-	-	-	-	-
Mount Sinai Hospital	-	-	-	-	-	1	-
Northwestern University LAPS	5	-	-	-	1	-	-
Ohio State University Comprehensive Cancer Center LAPS	12	-	-	-	-	-	-
Oregon Health and Science University	-	-	-	-	-	-	-
Pacific Cancer Research Consortium NCORP	4	-	1	-	-	-	-
Regents of the University of Michigan	2	4	-	5	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	1	-	-	-	-	-	-
The Don and Sybil Harrington Cancer Center	-	-	-	-	-	1	-
The Hawaii NCORP	1	-	-	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-	-	-	1	-	-
UC San Diego Moores Cancer Center	-	-	-	-	2	3	-
USC Norris Comprehensive Cancer Center LAPS	-	-	-	-	-	-	5
University of Colorado Cancer Center LAPS	-	-	-	-	1	-	-
University of Rochester LAPS	-	-	-	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	-	-	3	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	1	-	-	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	4	-	-	-	-	-	-
Wisconsin NCI Community Oncology Research Program	3	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	10	1	-	-	2	-	-
ALLIANCE	28	-	6	-	-	-	-
ECOG-ACRIN	16	-	9	-	-	-	-
NRG	13	1	10	-	-	-	-
Total	163	7	33	5	9	5	5

Early Therapeutics & Rare Cancers Committee

Accrual from trials that are open as of 6/30/2026 or have closed in the prior 18 months, by Institution and Study

	EA7211	EAY191	EAY191A3	EAY191A6
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	-	-	-	-
Cancer Research Consortium of West Michigan NCORP	-	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-	-
Carolinas Medical Center/Levine Cancer Institute	-	-	-	-
Cedars-Sinai Medical Center	-	5	-	-
CommonSpirit Health Research Institute	-	-	-	-
Duke University - Duke Cancer Institute LAPS	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	1	-	-	-
Froedtert and the Medical College of Wisconsin LAPS	-	-	-	-
Gulf South Clinical Trials Network (Gulf South NCORP)	-	-	-	-
Heartland Cancer Research NCORP	-	-	-	-
Henry Ford Hospital	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	-	-	-	-
Michigan Cancer Research Consortium NCORP	-	-	-	-
Moffitt Cancer Center	-	-	-	-
Mount Sinai Hospital	-	-	-	-
Northwestern University LAPS	-	-	-	-
Ohio State University Comprehensive Cancer Center LAPS	-	-	-	-
Oregon Health and Science University	-	1	-	-
Pacific Cancer Research Consortium NCORP	-	-	-	-
Regents of the University of Michigan	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	-	-
The Don and Sybil Harrington Cancer Center	-	-	-	-
The Hawaii NCORP	-	1	-	1
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	4	-	1
UC San Diego Moores Cancer Center	-	1	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-	-	-
University of Colorado Cancer Center LAPS	-	-	-	-
University of Rochester LAPS	1	-	-	-
University of Texas MD Anderson Cancer Center LAPS	-	10	2	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	-	-	-
Wisconsin NCI Community Oncology Research Program	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	-	-
ALLIANCE	-	-	-	-
ECOG-ACRIN	-	-	-	-
NRG	-	-	-	-
Total	2	22	2	2

